They then discuss the interactions between sildenafil and nitrates, other phosphodiesterase inhibitors, drugs affecting the metabolic clearance of sildenafil, antihypertensive drugs, renal dysfunction, and hepatic dysfunction. They also include recommendations on prescribing sildenafil to patients at clinical risk, how to manage an acute ischemic syndrome in patients taking sildenafil, and how to treat the hypotensive patient who has inadvertently taken sildenafil and a nitrate combination. The paper also includes a complete list of all organic nitrates and of drugs that inhibit the cytochrome P450 3A4 metabolic pathway. The site is sponsored by the Agency for Health Care Policy and Research, in partnership with the American Medical Association and the American Association of Health Plans. Guidelines can be found either by using the search engine provided or by browsing through the lists.
Users can also look at a list of organizations that have guidelines in the database.
The web site is updated weekly with new and revised guidelines. However, most information available to pharmacists is written at the healthcare provider level. This web site fills a gap, with patient information on drugs and disease states. The information is clearly labeled as a supplement to and not a substitute for the knowledge, expertise, skill and judgment of physicians, pharmacists or other healthcare professionals involved in patient care. Examples of leaflets contained in the database include women's health, liver problems and nervous system disorders.